Johnson’s responsibilities include leading global operations for Kindeva’s manufacturing and R&D facilities across the U.S. and UK. The company expects him to facilitate the expansion and opening of the company’s new aseptic injectable fill-finish site in Bridgeton, Missouri. He will also expand the company’s focus on bringing green propellants to commercial combination product manufacturing for more eco-friendly inhalers.
Johnson brings extensive life sciences leadership and manufacturing experience to Kindeva. Most recently, he served as head of global manufacturing and technical operations at Biogen. Previously, he held leadership roles at Catalent, Boston Scientific, Teradyne and Johnson & Johnson. He began his career in the U.S. Army, managing logistics and operations.
Kindeva CEO Milton Boyer called Johnson’s extensive CDMO experience “invaluable” to the company’s efforts to expand and innovate in the drug delivery space. He expects Johnson’s leadership skills and market expertise to help introduce the first 152a commercial green propellant line to the market.
“Kindeva’s commitment to more patient-centric, sustainable drug delivery systems as well as continued growth, especially over the past year, is exciting,” Johnson said. “I’m excited to join the Kindeva team to drive continued operational excellence and implement strategies that ensure the timely delivery of life-changing medications to patients worldwide.”
